Skip to search formSkip to main contentSkip to account menu

basiliximab

Known as: Ig gamma-1 chain C region, basiliximab [Chemical/Ingredient], chimeric mouse-human antiCD25 
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with… 
National Institutes of Health

Related topics

Related topics

9 relations
Drug AllergyGraft-vs-Host DiseaseInterleukin 2 Receptor Antagonists [MoA]Simulect

Broader (3)

Immunosuppressive AgentsMonoclonal AntibodiesRecombinant Fusion Proteins

Narrower (1)

basiliximab 20 MG Injection [Simulect]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Choice of induction regimens on the risk of cytomegalovirus infection in donor‐positive and recipient‐negative kidney transplant recipients
F.L. Luan, M. Samaniego, M. Kommareddi, J.M. Park, A.O. Ojo. Choice of induction regimens on the risk of cytomegalovirus… 
Highly Cited
2005
Highly Cited
2005
Everolimus and Basiliximab Permit Suppression by Human CD4+CD25+ Cells in vitro
Immunosuppressive drugs are essential for the prevention of acute transplant rejection but some may not promote long‐term… 
Highly Cited
2005
Highly Cited
2005
The renal‐sparing efficacy of basiliximab in adult living donor liver transplantation
The purpose of this study is to find out whether basiliximab administration will improve postoperative renal function by delaying… 
Highly Cited
2004
Highly Cited
2004
Interleukin‐2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage
A prospective evaluation was performed to study the potential benefits of the use of interleukin‐2 receptor antibody (IL‐2Rab) in… 
2003
2003
Cardiac transplantation across a positive prospective lymphocyte cross‐match in sensitized recipients
Abstract: Background: Although there is an increasing body of evidence for a deleterious effect of mismatched donor HLA antigens… 
Highly Cited
2003
Highly Cited
2003
A pilot protocol of a calcineurin‐inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function
Abstract: Background: The worsening shortage of cadaver donor kidneys has prompted use of expanded or marginal donor kidneys (MDK… 
Highly Cited
2002
Highly Cited
2002
Cyclosporine Microemulsion (Neoral®) Absorption Profiling and Sparse‐sample Predictors During the First 3 Months after Renal Transplantation
Recent data suggest that optimal cyclosporine (CsA) exposure early post‐transplant significantly reduces the risk of acute graft… 
Highly Cited
2002
Highly Cited
2002
Immunoprophylaxis with basiliximab, a chimeric anti–interleukin‐2 receptor monoclonal antibody, in combination with azathioprine‐containing triple therapy in liver transplant recipients
Acute graft rejection remains a major problem among additional sequelae in liver transplant recipients. Basiliximab, a chimeric… 
2001
2001
First experience with basiliximab in pediatric liver graft recipients
Abstract: Several studies have shown a significant reduction of acute cellular graft rejection in adult liver and kidney graft… 
Highly Cited
1999
Highly Cited
1999
Basiliximab. Point of view
The chimaeric monoclonal antibody basiliximab specifically binds the α subunit of the interleukin-2 (IL-2) receptor on activated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)